Interview timestamps:

02:20 Satellos

26:00 EVŌQ Nano

Antibiotic-resistant infections are a top 10 global health threat demanding urgent innovation.

A US-based nanotech company, EVŌQ Nano, has developed a novel nanoparticle that destroys bacteria from the inside – without triggering antimicrobial resistance (AMR).

The nanoparticle is already in development for an inhaled therapeutic for Cystic Fibrosis patients, as well as for antimicrobial medical devices and treatment of the surface of textiles. It is also being earmarked for applications in energy and agriculture.

The company’s multi-patented, high-volume laser nanofabrication process creates uniform, sub-10nm nanoparticles with distinct surface chemistry. The company said these properties represent a significant advancement in nanoscience with the potential for a wide range of applications.

We had a chance to have a wide-ranging conversation with the company’s CEO, Shaun Rothwell.

Satellos Bioscience

Satellos is a clinical-stage drug development company dedicated to developing medicines to treat degenerative muscle diseases.

It has created SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity.

SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for Duchenne muscular dystrphy.

Satellos is also leveraging its breakthrough research and proprietary discovery platform MyoReGenX, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development.

We had a chat with Satellos’ chief scientific officer, Phil Lambert, about the drug, and the recently-announced results.

To get in touch with guest suggestions, please email jim@deeptechdigest.com